Champions Oncology develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company provides Personalized Oncology Solutions that assist physicians in developing personalized treatment options for cancer patients through tumor specific data obtained from drug panels and related personalized oncology services.

Type
Public
HQ
Hackensack, US
Founded
2007
Size (employees)
79 (est)+32%
Champions Oncology was founded in 2007 and is headquartered in Hackensack, US
Report incorrect company information

Key People/Management at Champions Oncology

Ronnie Morris

Ronnie Morris

Chief Executive Officer
Angela Davies

Angela Davies

Chief Medical Officer

Champions Oncology Office Locations

Champions Oncology has offices in Hackensack, Baltimore and London
Hackensack, US (HQ)
307 1 University Plaza Dr
Baltimore, US
602 855 N Wolfe St
London, GB
2 Royal College St
Show all (3)
Report incorrect company information

Champions Oncology Financials and Metrics

Champions Oncology Financials

Champions Oncology's revenue was reported to be $11.18 m in FY, 2016 which is a 26.2% increase from the previous period.
USD

Revenue (Q3, 2018)

15.3 m

Net income (Q3, 2018)

(844 k)

EBIT (Q3, 2018)

(755 k)

Market capitalization (25-Apr-2018)

31.1 m

Cash (31-Jan-2018)

1.1 m
Champions Oncology's current market capitalization is $31.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

11.6 m8.9 m11.2 m

Revenue growth, %

(23%)26%

Sales and marketing expense

3.4 m

General and administrative expense

5.2 m
Quarterly
USDQ2, 2018Q3, 2018

Revenue

5.2 m15.3 m

Sales and marketing expense

551 k1.9 m

General and administrative expense

954 k3.2 m

R&D expense

1.1 m3.3 m
Annual
USDFY, 2014FY, 2015FY, 2016

Cash

5.9 m9.4 m

Accounts Receivable

1.3 m1.1 m1.3 m

Inventories

383 k346 k443 k

Current Assets

7.6 m10.8 m4.3 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

7.6 m5.8 m3.1 m575 k182 k6.8 m4.2 m3.3 m4.5 m4.3 m3.5 m430 k660 k1.1 m

Accounts Receivable

1.5 m3.1 m925 k1.1 m1.1 m1.5 m1.9 m2.1 m1.6 m1.9 m2 m2.7 m2.6 m2.9 m

Current Assets

9.3 m9.2 m4.4 m2.1 m1.5 m8.6 m6.3 m5.8 m6.4 m6.7 m6.1 m3.5 m3.5 m4.2 m

PP&E

387 k421 k411 k395 k469 k445 k420 k514 k590 k561 k672 k2.1 m2 m2 m
Annual
USDFY, 2014FY, 2015FY, 2016

Net Income

(7.4 m)(13.1 m)(10.4 m)

Depreciation and Amortization

213 k214 k156 k

Accounts Payable

(223 k)433 k482 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q3, 2018

Net Income

(844 k)

Depreciation and Amortization

253 k

Accounts Payable

1.3 m1.6 m1.4 m1.4 m1.3 m1.5 m1.5 m1.2 m1.3 m124 k

Cash From Operating Activities

(1.2 m)
USDY, 2018

Financial Leverage

15 x
Show all financial metrics
Report incorrect company information